Pelthos Therapeutics (PTHS)

:PTHS

PTHS

Pelthos Therapeutics

RESEARCH TOOLSreports

Want to see PTHS full AI Analyst Report?

Pelthos Therapeutics (PTHS) Price & Analysis

72 Followers

PTHS Stock Chart & Stats

$23.02

Market closed

$23.02

Day’s Range― - ―

52-Week Range$9.00 - $54.29

Previous CloseN/A

VolumeN/A

Average Volume (3M)30.94K

Market Cap

$83.89M

Enterprise Value$33.03M

Total Cash (Recent Filing)$18.02M

Total Debt (Recent Filing)$34.83M

Price to Earnings (P/E)―

Beta1.70

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding3,355,543

10 Day Avg. Volume22,109

30 Day Avg. Volume30,941

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)1.50

Price to Sales (P/S)3.47

P/FCF Ratio-2.57

Enterprise Value/Market Cap0.39

Enterprise Value/Revenue1.97

Enterprise Value/Gross Profit3.14

Enterprise Value/Ebitda-1.10

Forecast

1Y Price Target

$57.14

Price Target Upside148.23% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Market AccessBroader commercial and Medicaid coverage and new pharmacy benefit contracts improve patient access and should support continued prescription growth.

Market DemandShift from inventory stocking to dispensed prescriptions indicates real patient demand for the product and supports a more durable revenue profile.

Prescriber AdoptionExpanding prescriber adoption across dermatology and pediatric settings, with early evidence of repeat use, supports broader uptake and deeper market penetration.

Bears Say

Commercial ExecutionCommercial and launch risks for Zelsuvmi and recently acquired products could limit sales growth and slow market adoption despite clinical advantages.

Financial ObligationsHigher selling and administrative expenses combined with the company's term loan obligations raise fixed costs and can compress profitability.

Reimbursement PressureIncreasing payer contracting and higher gross-to-net pressures could meaningfully reduce net revenue as the product scales.

Pelthos Therapeutics News

Pelthos Therapeutics says John Gay to succeed Francis Knuettel II as CFO

Pelthos Therapeutics (PTHS) announced John Gay has been appointed CFO, effective April 10. Gay succeeds Francis Knuettel II,...

21d ago

PTHS

Pelthos Highlights Infectious Disease Portfolio at Investor Meetings

An update from Pelthos Therapeutics ( ($PTHS) ) is now available. Pelthos Therapeutics Inc., based in Durham, N.C.,...

18d ago

PTHS

Pelthos Therapeutics Appoints John M. Gay as CFO

Pelthos Therapeutics ( ($PTHS) ) just unveiled an update. On April 6, 2026, Pelthos Therapeutics’ board appointed John...

21d ago

PTHS

Pelthos Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Pelthos Therapeutics (PTHS) with an Overweight rating and $50 price target Pelthos is...

1M ago

PTHS

Pelthos Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Pelthos Therapeutics (PTHS) with an Overweight rating and $50 price target Published first...

1M ago

PTHS

Pelthos Therapeutics doses first patient in CT2000 trial

Pelthos Therapeutics (PTHS) announced that the first patient has been dosed in a Phase 1b/2a clinical trial evaluating...

1M ago

PTHS

Pelthos Therapeutics Inc trading resumes

11:13 EDT Pelthos Therapeutics (PTHS) Inc trading resumes Published first on TheFly – the ultimate source for real-time,...

1M ago

PTHS

Pelthos Therapeutics Inc trading halted, volatility trading pause

11:08 EDT Pelthos Therapeutics (PTHS) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate...

1M ago

PTHS

Pelthos Therapeutics price target raised to $62 from $60 at Oppenheimer

Oppenheimer analyst Jeff Jones raised the firm’s price target on Pelthos Therapeutics (PTHS) to $62 from $60 and...

1M ago

PTHS

Pelthos Highlights 2025 Results and Portfolio Expansion Progress

Pelthos Therapeutics ( ($PTHS) ) has issued an update. On March 19, 2026, Pelthos Therapeutics reported fourth-quarter and...

1M ago

PTHS

Pelthos Therapeutics reports Q4 EPS ($6.87) vs. ($3.19) last year

Reports Q4 Zelsuvmi revenue $9.1M vs. $7.1M vs. last year. CEO Scott Plesha commented, “We are delighted with...

1M ago

PTHS

PTHS Earnings this Week: How Will it Perform?

Pelthos Therapeutics Inc. (PTHS) is scheduled to report 4th quarter earnings on 03/19/2026. Regarding Q4 estimates, Wall Street...

2M ago

PTHS

Pelthos Therapeutics initiated with an Overweight at Piper Sandler

Piper Sandler analyst David Amsellem initiated coverage of Pelthos Therapeutics (PTHS) with an Overweight rating and $48 price...

2M ago

PTHS

Pelthos Therapeutics price target lowered to $55 from $57 at Roth Capital

Roth Capital lowered the firm’s price target on Pelthos Therapeutics (PTHS) to $55 from $57 and keeps a...

2M ago

PTHS

PTHS FAQ

What was Pelthos Therapeutics’s price range in the past 12 months?

Pelthos Therapeutics lowest stock price was $9.00 and its highest was $54.29 in the past 12 months.

What is Pelthos Therapeutics’s market cap?

Pelthos Therapeutics’s market cap is $83.89M.

When is Pelthos Therapeutics’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Pelthos Therapeutics’s earnings last quarter?

Currently, no data Available

Is Pelthos Therapeutics overvalued?

According to Wall Street analysts Pelthos Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Pelthos Therapeutics pay dividends?

Pelthos Therapeutics does not currently pay dividends.

What is Pelthos Therapeutics’s EPS estimate?

Pelthos Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Pelthos Therapeutics have?

Pelthos Therapeutics has 3,355,543 shares outstanding.

What happened to Pelthos Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Pelthos Therapeutics?

Currently, no hedge funds are holding shares in PTHS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Pelthos Therapeutics Stock Smart Score

Neutral

Company Description

Pelthos Therapeutics

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.

Pelthos Therapeutics (PTHS) Earnings & Revenues

Historic Earnings Reports

PTHS Earnings Call

Q4 2026

0:00 / 0:00

PTHS Stock 12 Month Forecast

Average Price Target

$57.14

▲(148.23% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","76":"$76","25.75":"$25.8","42.5":"$42.5","59.25":"$59.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":57.14285714285714,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$57.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$48.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,25.75,42.5,59.25,76],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.3,25.430769230769233,29.56153846153846,33.69230769230769,37.823076923076925,41.95384615384616,46.08461538461539,50.21538461538462,54.346153846153854,58.476923076923086,62.60769230769232,66.73846153846155,70.86923076923077,{"y":75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.3,24.057142857142857,26.814285714285717,29.571428571428573,32.32857142857143,35.08571428571429,37.84285714285714,40.6,43.35714285714286,46.114285714285714,48.87142857142857,51.62857142857143,54.385714285714286,{"y":57.14285714285714,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.3,23.353846153846156,25.407692307692308,27.46153846153846,29.515384615384615,31.56923076923077,33.62307692307692,35.676923076923075,37.730769230769226,39.78461538461538,41.83846153846154,43.892307692307696,45.94615384615385,{"y":48,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.5,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":12.5,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":10.2,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.86,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.46,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.46,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.3,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.16,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.3,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >